secwatch.observer — SEC 8-K summary
======================================

Issuer:     Syndax Pharmaceuticals Inc (SNDX)
CIK:        0001395937
Form:       8-K
Filed at:   2023-05-18T23:59:59+00:00
Accession:  0000950170-23-022802
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 3.03, 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Syndax shareholders approve increase in authorized shares from 110M to 210M
---------------------------------------------------------------------------

- Amendment to certificate of incorporation increases authorized shares: 200M common stock + 10M preferred stock.
- All four proposals passed at May 17, 2023 annual meeting; directors elected with majority support.
- Advisory vote on executive compensation passed with 58.1M for vs 0.8M against; auditor ratified.
- Increase provides flexibility for potential future equity financings or corporate actions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1395937/000095017023022802/0000950170-23-022802-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1395937/000095017023022802/sndx-20230517.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-022802

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer